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Diﬀerent species have been used to reproduce myocardial infarction models but in the last years mice became the animals of
choice for the analysis of several diseases, due to their short life cycle and the possibility of genetic manipulation. Many techniques
are currently used for cardiovascular imaging in mice, including X-ray computed tomography (CT), high-resolution ultrasound,
magnetic resonance imaging, and nuclear medicine procedures. Cardiac positron emission tomography (PET) allows to examine
noninvasively, on a molecular level and with high sensitivity, regional changes in myocardial perfusion, metabolism, apoptosis,
inﬂammation, and gene expression or to measure changes in anatomical and functional parameters in heart diseases. Currently
hybrid PET/CT scanners for small laboratory animals are available, where CT adds high-resolution anatomical information. This
paper reviews mouse models of myocardial infarction and discusses the applications of dedicated PET/CT systems technology,
including animal preparation, anesthesia, radiotracers, and images postprocessing.
1.Introduction
Cardiovascular diseases, such as coronary heart disease
(CHD), are common causes of morbidity and mortality
in developed countries. Currently CHD is a relevant cause
of permanent disability in workers and congestive heart
failure, which is frequently secondary to myocardial infarc-
tion (MI). Despite progress in the diagnosis and treatment
of CHD, appropriate animal models play a central role
to investigate the mechanisms involved in the pathogen-
esis and for the advancement of diagnosis and therapies.
Rodents, in particular mice, are often used in cardio-
vascular research, since they are not expensive, easy to
handle and to house, are easily prone to genetic manipu-
lations and show anatomic similarity in developmental and
postnatal heart compared with humans. Therefore, conven-
tional wild-type and genetically altered mice are becoming
interesting models for better understanding the pathogenesis
and improvement in diagnosis, prevention, and therapy
of CHD in humans. Noninvasive in vivo imaging has
acquired a critical role in mouse cardiovascular research;
however, the small size and rapid rate of the mouse heart
pose signiﬁcant challenges for cardiac imaging, requiring
expensive equipment and established expertise (Figure 1).
Since the left ventricle wall is thinner than 1mm, high
spatial resolution is mandatory. At the same time, the rapid
h e a r tm o v e m e n tr e q u i r e sh i g ht e m p o r a lr e s o l u t i o n .Table 1
indicates several imaging techniques that are currently used
for morphological and functional phenotyping of mouse
cardiovascularsystem,includinghigh-resolutionultrasound,
X-ray computed tomography (CT), magnetic resonance,
and nuclear medicine procedures. Molecular imaging with
positron emission tomography (PET) allows evaluating, in a
non-invasive and longitudinal manner, biological processes2 Journal of Biomedicine and Biotechnology
Table 1: Principal characteristics of small animal imaging techniques in cardiovascular research.
Imaging
technique
Physical
principle
Spatial
resolution Advantages Disadvantages
UBM High frequency
sound waves 50μm Real-time cardiovascular
morphofunctional assessment
Strongly operator dependent,
diﬃcult assessing of right
ventricle
CT X-rays 100μm Left ventricle morphology Radiation dose
MRI High intensity
magnetic ﬁeld 200μm High tissue contrast and
functional parameters Most expensive and availability
SPECT Gamma
emitters
Max 0.62mm
FWHM
Molecular imaging, myocardial
metabolism and perfusion,
10−10-10−11 Ms e n s i t i v i t y
Low spatial resolution, radiation
dose
PET Positron
emitters
Max 1mm
FWHM
Molecular imaging, myocardial
metabolism and perfusion,
10−11-10−12 Ms e n s i t i v i t y
Low spatial resolution, radiation
dose
UBM: ultrasound biomicroscopy; CT: computed tomography; MRI: magnetic resonance imaging; SPECT: single-photon emission computed tomography;
PET: positron emission tomography; FWHM: full width at half maximum.
Figure 1: Longitudinal and transversal dimensions (mm) of mouse
heart.
at a cellular and subcellular level in early steps of heart
diseases, to perform quantitative analysis, to study apopto-
sis, angiogenesis, hypoxia, inﬂammation, receptor density,
and gene expression. In spite of the great speciﬁcity and
sensitivity of PET, molecular imaging approach can take
advantage from simultaneous acquisition of morphological
information for localization and quantiﬁcation. Therefore,
hybrid imaging with PET/CT systems is becoming the most
used approach in cardiovascular imaging. In this paper we
review mouse models of myocardial infarction and discuss
the applications of dedicated PET/CT systems technology,
including animal preparation, anesthesia, radiotracers, and
images postprocessing.
2. Models of MyocardialInfarction
In an animal model the induced disorder should closely
resemble the disorder in human. None of the currently avail-
able animal models can entirely reproduce the full spectrum
ofcardiovasculardiseasesinhumans.Rodents,especiallyrats
and mice, are commonly used in cardiovascular research
because they are less expensive and are easier to handle and
tohousecomparedtolargeanimals[1].Sinceabroadvariety
of genetically modiﬁed mice are produced and knockin and
knockout techniques are well developed on mice, mouse
models are increasingly adopted to study cardiovascular
human diseases and to identify new therapeutic targets. The
most frequently used include MI or ischemia-reperfusion by
ligation of the left coronary artery [2, 3]. Despite several
anatomic diﬀerences, the value and clinical translatability
of mouse models of cardiac diseases have been proven. The
mouse heart is similar to the human concerning ventricular
structure and valves. The major anatomical diﬀerences are
seen in the atria and venous pole of the heart (Figure 2). In
human, left atrium receives four pulmonary veins, while in
themousethepulmonaryveinsjoininasinglevessel.During
organogenesis, in human left cranial caval vein regresses and
the proximal portion becomes the coronary sinus, while the
distal portion gives rise to the ligament of Marshall and the
obliquevein [4].Inthemouse,theleftcranialcavalvein does
not regress and persist in postnatal life. These diﬀerences in
venous tributaries into atrial chambers are the likely reasons
for the relatively small size of atria in murine heart [5]. The
mouse coronary anatomy has some diﬀerences compared to
human. Mice have a single septal coronary artery, arising
from separate ostia from the right sinus of Valsalva or as a
proximal branch of the right coronary artery, while in man
the interventricular septum is perfused by septal perforator
arteries arising from the left anterior descending or posterior
descending coronary arteries. Mouse left coronary artery
does not divide proximally into left anterior descending
and circumﬂex artery, but courses obliquely across the
left ventricular (LV) free wall and branches in a variableJournal of Biomedicine and Biotechnology 3
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Figure 2:Tridimensionalreconstructionofmouseheart,represent-
ing the peculiar features of venous pole and left coronary artery
anatomy.
fashion, similar to the ramous intermedius artery in man.
The right coronary artery branches proximal into a right
ventricular and circumﬂex vessel supplying the LV posterior
wall. Therefore, the distinct mouse coronary artery anatomy
results in diﬀerent regionality of infarction compared with
human, because ligation of the left coronary artery in mice
produces ischemia in the anterolateral, posterior, and apical
regions of the heart, sparing the septum [2]. Also the
anatomy of conduction system is diﬀerent from human,
because the sinoatrial node is located in the superior caval
vein above its junction with the right atrium, not in the
atrium itself [6]. Mouse model of myocardial ischemia has
highlighted the mechanisms of infarct and LV remodeling
and is often the ﬁrst choice for testing new therapies such
as stem cell myocardial repair. Animal models mimicking
the characteristics and development of human MI and heart
failure related to CHD have been developed with various
strategiesandmethods.InhumansCHDisrelatedtochronic
narrowing by atherosclerotic plaques or by acute occlusion
by thrombosis of coronary arteries. In animals, atherosclero-
sis can be reproduced inducing hypercholesterolemia by fat-
/cholesterol- rich diet or by genetic manipulation. However,
time point and site of coronary occlusion occur accidentally
inthesemodelsand,inthelattercase,theetiologyisdiﬀerent
from that naturally occurring in humans. Various pathologic
conditions mimicking human cardiovascular diseases can be
induced by microsurgery. For example, surgical induction
of narrowing or occlusion of coronary arteries allows
facilitating a precise timing, location, reproducibility, and
extent of coronary disease. According to the duration and
extent of coronary blood ﬂow impairment, surgical models
can be classiﬁed as MI, cardiac ischemia-reperfusion injury,
and chronic cardiac ischemia. In recent years, the mouse is
the species increasingly used to characterize MI induced by
coronary artery ligation. This is the major animal model
of LV dysfunction progressing to failure. A main technical
challenge to perform cardiovascular surgery in mice is the
littlesizeofmouseheartandcoronaryarteries.Amicroscope
is required to clearly detect and bind the small left coronary
artery. Moreover, dedicated microsurgical instruments, thin
sutures and needles, and a customized mouse ventilator
should be employed. To perform surgery, the mouse is
anesthetized with intraperitoneal or inhalant agents. It is
important to not disturb the animal prematurely, since this
will induce stress and aﬀect the quality of the subsequent
procedure. After an adequate depth of anesthesia is attained,
the mouse is ﬁxed in a supine position on a heating table
to prevent hypothermia and is intubated to provide assisted
ventilation. Tracheal intubation of mice is challenging, due
to their small mouth and then the diﬃculty to visualize vocal
cord opening. If performed by nontrained operators, there is
a high risk of pharyngeal or tracheal damage, such as perfo-
rationorstenosis.Intubationcanbemadewithacustomized
tracheal cannula or a modiﬁed 18–20 gauge intravenous
Teﬂon catheter, of about 25mm of length, inserted through
the oral cavity or after tracheotomy/tracheostomy. Visualiza-
tionofvocalcordopeningcanbefacilitatedwithappropriate
positioning and using dedicated “self-made” device [7–12].
A drop of 1% lidocaine can be applied on the tip of the
tracheal cannula to reduce laryngeal reﬂex. After intubation,
the mouse is connected to a mouse ventilator, providing
oxygen 2 liters/min and in case an inhalant anesthetic, with
a tidal volume of 200μL and a respiratory rate of about 133
breaths/min. Prior to the incision, the chest is trichotomized
and disinfected with iodopovidone solution, and 0.1mL of
0.1% lidocaine is injected subcutaneously. The thoracotomy
is performed by a transverse 5mm incision of the left fourth
intercostal space, 2mm away from the left sternal border. It
is important to avoid bleeding caused by damage intercostal
or internal thoracic veins. Chest retractor is gently inserted
to facilitate heart exposition. The pericardial sac is gently
opened, taking care to avoid the rupture of the wall of the
left superior vena cava. The left coronary artery is visualized
as a pulsating bright red vessel, running in the middle of the
heart wall from the left atrium toward the apex. Ligation
is performed with a 7-0 suture passed with a thin needle
undertheartery,1-2mmlowerthanthetipoftheleftauricle,
which induces 40–50% ischemia of the left ventricle. It is
important to not enter the cavity of the ventricle with the
needle, but also to not be too superﬁcial, as suture will cut
through the wall ventricle. Blanching of the tissue distal to
the ligation can recognize the occlusion of the artery. It is
important to overinﬂate lungs by shutting oﬀ with a ﬁnger
the outﬂow of the ventilator for 1-2 seconds. In fact, the4 Journal of Biomedicine and Biotechnology
lungs could be partially compressed by the retractor and
their collapse could result in respiratory distress and poor
recovery after surgery. The chest cavity is closed by bringing
together the 4th and the 5th ribs, muscles, and skin with 7-
0 absorbable sutures. The duration of the whole procedure
is reported of about 20 minutes for trained personnel. The
permanent occlusion of left coronary artery is followed by an
extensivemyocardialremodeling,ahypertrophyoftheviable
myocardium and thinning of the necrotic area [13]. Genetic
background, age, and sex of animals should be considered
because they can inﬂuence both infarct size and the disease
progression [14, 15]. Similar to the MI animal models,
to perform ischemia-reperfusion models the left coronary
arteryislegated,butasmallplastictubeisplacedbetweenthe
legated vessel and the node, allowing for easier and safe relief
of the occlusion. Ischemia can be veriﬁed by sudden regional
paleness of the myocardium, whereas reperfusion is veriﬁed
bytheappearanceofhyperemiainthepreviouslypaleregion.
During the period of occlusion, the chest opening should
be covered with a sterile gauze to prevent drying and loss
of heat. This model is characterized by a high inﬁltration
of inﬂammatory cells, attenuated ﬁbrotic remodeling and
angiogenesis in the necrotic area [13]. To minimize the
inﬂuence of surgery on inﬂammatory process, a “closed
chest” ligation model of myocardial ischemia-reperfusion
injury in the mouse has also been developed: brieﬂy, after
thoracotomy, a thin suture is passed under the left coronary
artery and the end of the suture are inserted into a piece of
polyethylene-10 tubing and exteriorized through the chest
wall [16]. Then thoracic incision is closed and ischemia-
reperfusion experiment is performed a few days later, pulling
or releasing the suture ends, when inﬂammatory process
induced by surgery is ended. The surgical murine model
of MI is diﬀerent from human pathological condition for
several aspects: left coronary artery ligation produces in
mice a transmural MI, whereas in human the development
of collateral circulation and the potential cardioprotective
eﬀects of repeated mild ischemic events associated with
CHD produce smaller, nontransmural infarct. In 1994,
Miller and colleagues showed that “preconditioning” in the
myocardium can induce a reduction of the infarct size of
about 50%. For preconditioning, the mouse undergoes three
cyclesof5minutesofarteryocclusion,followedby5minutes
of reperfusion, and then 30 minutes of artery occlusion
followed by 2 hours of reperfusion. Mortality associated with
MI induction in mice is about 10%, due to acute malignant
arrhythmias such as ventricular ﬁbrillation after reperfusion
or within 1 hour after surgery, that can be prevented by
intraperitoneal injection of lidocaine (6mg/kg) [13].
3.CardiacPET/CTImaging
Traditional cardiac imaging is based on detection of changes
in the anatomy and physiological features of heart, such
as blood ﬂow or contractile function. Instead, molecular
imaging is characterized by visualization and measurement
of biochemical and cellular mechanisms of diseases, includ-
ing altered energy metabolism, inﬂammation, apoptosis,
thrombosis, and angiogenesis, thus improving early diag-
nosis and therapeutic approaches. Cardiac imaging in mice
is diﬃcult, due to the small ventricle volume and high
heart rate. The use of molecular imaging in preclinical
cardiovascular research has become possible by advances
in imaging technology. In the last years, small animal PET
systems with high spatial resolution and great sensitivity
have been developed. The advantages of PET include
higher sensitivity enabling dynamic imaging, creation of
radiolabeled probes with natural radioisotopes that do
not alter chemical behavior, well-established methods for
attenuation correction, and the potential of absolute and
semiquantitative accurate image quantiﬁcation. PET allows
measurement of functional processes like myocardial blood
ﬂow,cardiacoutput,metabolism ofglucoseorfreefattyacid,
or oxygen consumption in absolute units or, more simply,
in a semiquantitative manner. Dynamic scans are required
to measure the arterial input function and the tissue time
activity curve. In humans and in larger animal models, these
parameters are evaluated through repeated blood samples,
or noninvasively by assessing the activity of the arterial
blood pool in the LV cavity on PET images. Catheter-
based arterial blood sampling is the gold standard method
for measuring the input function in mice. Nevertheless, in
mice arterial sampling is technically diﬃcult because of the
relatively small diameters and fragility of the mouse blood
arteries [17]. In addition, the total blood volume of a mouse
is very limited (1.7mL), making repeated blood sampling
impossible without aﬀecting the homeostasis of the mice.
To minimize blood loss and diﬃculty in sampling blood
from a mouse during a dynamic small animal PET scan,
a microblood sampling technique has been developed [18],
but the number of blood samples that can be withdrawn
is limited. To avoid these problems, various methods have
been proposed to estimate the input function noninvasively,
suchasthederivationoflivertime-activitycurvefromsmall-
animal PET dynamic images [17, 19]o rm e a s u r e m e n to f
blood pool activity from a LV volume of interest [20–24].
However, in small animal imaging, hearts and arteries are
small compared with the scanner spatial resolution and
in association with cardiac and respiratory motion causes
blurring and partial volume eﬀect artifacts. The correction
of the partial volume related underestimation of the blood
tracer concentration could be made determining recovery
coeﬃcient by diﬀerent sizes rod phantoms [22] or using a
four-dimensional virtual mouse phantom [25]. Moreover,
the fast heart rate needs the correction for tracer recircu-
lation. Since blood samples could not be obtained rapidly
during the initial bolus transits through the central circula-
tion, an early time point 20–35 seconds after injection has
been proposed for blood-sampling-derived values. At this
time, equivalent to several circulation times, the radiotracer
concentration is relatively constant [20]. Implementation of
clustering [26] or factor analysis algorithms [27]e n a b l e s
minimally invasive extraction of accurate input functions
and myocardial time-activity curves from dynamic micro-
PET images of rodents without the need to draw regions
of interest, and overcoming the limitation related to partial-
volume eﬀect, spillover from the myocardium and motionJournal of Biomedicine and Biotechnology 5
blurring. Therefore, although the quantiﬁcation of the
metabolic rate of energetic substrates utilization improves
the accuracy of measuring the extent of the infarct, in
mice are commonly adopted semiquantitative approaches
for analysis of the distribution of radiotracers. Measurement
of infarct size is an important clinical goal for prognostic
assessment and evaluation of therapeutic interventions [28].
Although the quantiﬁcation of infarct size has been well-
established in humans, this approach is more challenging
in small animals due to their smaller size. In cardiovascular
research, histological measurements are widely accepted as
the gold standard for quantifying infarct size, also to validate
imaging-based approach. Nevertheless, histomorphometry
cannot provide serial measurements in the same animal over
time, which are useful to monitor the evolution of a disease
or the response to a treatment. Therefore, there is a great
interest to develop an accurate and noninvasive method to
evaluate infarct size in living mice, improving the knowledge
of metabolic and functional changes related to MI and the
eﬃcacy of interventional, pharmacological, or molecular
therapies. Several imaging-based approaches to measure
infarct size have been developed on animal models. It has
been reported that infarct size quantiﬁcation in mice can be
obtained in an accurate and repeatable way with CT [29],
magnetic resonance [30], single-photon emission computed
tomography (SPECT) [31], or PET [32]. In particular, PET
has several advantages, such as high spatial resolution and
sensitivity. Since tridimensional images can be reconstructed
from PET datasets, this technique is more suitable than oth-
ers,suchas2Dechocardiography,tostudyMImodels,which
are characterized by greatly modiﬁed ventricular shape and
irregularwallthickness[14].Furthermore,withtheadventof
dedicated image reconstruction and quantiﬁcation software,
it is now possible to perform quantitative clinical measures
in rodent heart.
Disadvantages of PET include the use of ionizing radia-
tion and the physic intrinsic limit to the maximum spatial
resolution achievable. Currently most micro-PET imaging
systems are fused with micro-CT, to create hybrid-imaging
systems that overcome the inherent low resolution of the
very sensitive nuclear imaging techniques and provide the
site of molecular tracers uptake in greater anatomic detail.
Hybrid imaging systems will facilitate the translation of
molecular imaging-based approaches to man. CT is also
useful to perform accurate correction for partial volume
errors. Disadvantages of CT include the use of ionizing
radiation and the limited spatial resolution achievable in
vivo, related to the radiation dose administered to the
animals.
4. PET Tracers for Models of
MyocardialInfarction
Alterations in myocardial substrate metabolism are critical
in the pathogenesis of many cardiovascular diseases. MI
is associated with numerous biochemical and functional
changes in the necrotic tissue, in the area at risk, and in
the remote myocardium. PET imaging can provide in vivo
a noninvasive, serial and quantitative assessment of myocar-
dial perfusion, metabolism, apoptosis, and gene expression.
Moreover, electrocardiographic and respiratory gating PET
imaging can also be used to analyze anatomic and functional
parameters, such as LV shape, end-diastolic and end-systolic
volumes, stroke volume, cardiac output, ejection fraction,
and regional contractility [32]. The principal characteristics
of the most commonly used PET tracers are illustrated in
Table 2. PET radiotracers used for evaluation of myocardial
blood ﬂow include N-13 ammonia, rubidium-82, and O-
15 water [33]. However, their short half-life limits their
widespread clinical use, because of the need for nearby
cyclotron or generator. Among these, N-13 ammonia is the
most widely used in preclinical studies, due to its rela-
tively longer half-life of ten minutes, the high myocardium
extraction, and reduced persistence in blood pool [34]. F-
18 ﬂuorodeoxyglucose (FDG) is the most widely used PET
tracer and its uptake provides an established method in
clinical practice to measure tissue viability in patients with
advanced CHD and impaired LV function. Compared with
the other tracers, FDG is more readily available in most
PET centers and allows for better resolution images [35].
FDG traces myocyte glucose uptake and phosphorylation
and can be used to quantify regional myocardial glucose
metabolism in normal mice and in those with myocardial
infarction (Figure 3). The uptake of FDG reﬂects the activity
of various glucose transporters and hexokinase in manner
similar to glucose, but unlike glucose-6-phosphate, FDG-
6-phosphate is not further metabolized and is trapped
into the cells, enhancing imaging quality. This radiotracer
is also useful to study inﬂammation in course of acute
myocardial ischemia-reperfusion injury and LV remodeling.
As an alternative to glucose metabolism, PET studies with
a variety of compounds with similar structure to the fatty
acids radiolabeled with [18F] are useful for studying cardiac
metabolism, since an ischemic event induces the use of
glucose as preferential energy substrate instead of fatty
acids, for a long time. C-11 acetate has been proposed as a
marker of myocardial viability, because it evaluates residual
oxidative metabolism, that is preserved in dysfunctional
b u tv i a b l em y o c a r d i u m ,w h e r e a si ti ss e v e r e l yd e p r e s s e di n
irreversibly dysfunctional segments [27]. In the literature it
hasbeen described preclinical studies in ratwith[18F]-RGD,
a cyclic peptide that speciﬁcally recognizes receptors ανβ3,
andusefultoevaluateangiogenesisaftermyocardialischemia
[36] and with 11C-epinephrine, demonstrating impaired
uptake and storage of catecholamines in the myocardium
after ischemia induction [37].
5.Technological FeaturesofDedicated
PET/CT Systems
The development of PET systems dedicated to small labora-
tory animals started in the early 1990s. The ﬁrst dedicated
scanner commercialized was the “RatPET” in 1995 [38].
Since then, the main objective has been the improvement
of the performances of these devices, considering that heart
size is 10 times smaller and heart rate is 10 times faster6 Journal of Biomedicine and Biotechnology
Table 2: Principal characteristics of PET tracers for cardiovascular imaging.
Tracer Production Half-life Extraction Myocardial uptake mechanism
13N-ammonia Cyclotron 10min 80% Diﬀusion/metabolic trapping (perfusion)
82Rubidium Generator 78sec 50–60% Na/K-ATPase (perfusion)
15O-water Cyclotron 2.1min 100% Free diﬀusion (perfusion)
F-18 FDG Cyclotron 110min 1–3% Glucose transport/hexokinase (viability)
PET: positron emission tomography; Na/K-ATPase: sodium/potassium-ATPase; FDG: ﬂuorodeoxyglucose.
Figure 3: [18F] FDG cardiac PET/CT in a normal mouse (top) and in a mouse with myocardial infarction (lower). FDG cardiac uptake is
uniform in the normal mouse, while there is an area of absent uptake in the anteroapical region of the mouse with myocardial infarction.
in mice than humans. It is well known that PET is char-
acterized by two intrinsic physical limits to the maximum
spatial resolution achievable: the ﬁnite range of positron
and the acollinearity of the two annihilation photons. It
has been estimated that the distance which F-18 travels
prior to annihilation produces a blurring eﬀect of about
0.1–0.2mm, whereas the deviation of annihilation photons
from the 180◦ direction will produce an additional blur of
0.3mm for a 15cm detector diameter scanner. Therefore,
the highest theoretically resolution achievable with F-18 is
about 0.6mm. Dedicated systems to date available have
a spatial resolution between 1 and 2mm full width at
half maximum (FWHM) [39–41]. Problems related to
nonuniformityofspatialresolutioncanbelimitedmeasuring
depth of interaction of gamma rays in detectors composed of
two joined scintillators with diﬀerent decay time constant,
for example LSO and GSO crystals. Nowadays the small
animalscannerwithhigherspatialresolutionischaracterized
b yad e t e c t o rs y s t e mf o r m e db yl a y e r so fl a m i n a t e dl e a d
with several holes that convert the incident gamma rays
in electrons, and gas ionization chambers that detect these
electrons. This peculiar detector system, associated with
the use of a “resolution recovery” reconstruction algorithm,
allows to achieve a spatial resolution of 1mm FWHM [41].
System sensitivity, deﬁned as the fraction of radioactive
decays detected per volumetric resolution elements, is the
other important parameter aﬀecting image quality. The
detector material, thickness, and geometry are the main
factors aﬀecting sensitivity. Currently both human and
preclinicalPETscannersdetectabout2–5%ofthecoincident
annihilation photons at the center of ﬁeld of view. The
main challenge of dedicated imaging systems is to obtain at
the same time a high spatial resolution and sensitivity. The
diﬃculty to reach this goal is in the design and realization
of the detectors. To achieve a high spatial resolution in
a dedicated PET scanner with inorganic crystals (BGO,
LSO(Ce), GSO(Ce)) detectors, the size of the crystals cross-
section must be reduced. As a consequence, the solid angleJournal of Biomedicine and Biotechnology 7
covered by a single detector is limited, decreasing the system
sensitivity.Moreover,areductionofcrystalssizeincreasesthe
number of gamma rays obliquely incident on their surface,
causing parallax error that degrades spatial resolution from
the center toward the edge of the ﬁeld of view. On the other
hand, the increase in the numbers of discrete small crystals
poses some diﬃculties in terms of light collection and
readout electronics. Theoretically, the coincidence photon
detection eﬃciency should be improved by a factor of 1000
scaling from clinical to mouse imaging, but it is possible to
achievea200-foldincreasein2Danda30-foldincreasein3D
data acquisition mode. The resolution-sensitivity oﬀset also
strongly aﬀects dynamic scans, because reconstruction of
shorttimeframesofPETdatamayresultinunacceptablelow
signal-to-noise ratio [40]. Iterative statistical algorithms can
optimize tradeoﬀ between signal-to-noise ratio and spatial
resolution [42]. Image quality is also inﬂuenced by the total
amount of radioactivity in the ﬁeld of view, and the scan
t i m e .I no r d e rt oc o l l e c ta na d e q u a t ea m o u n to fe v e n t sf o r
good quality image reconstruction, administered dose can
be increased securely for probes of endogenous compounds
such as the analogue of glucose FDG, overcoming some of
the sensitivity limitations. For probes targeting biological
markers in nanomolar concentration in tissues, an increase
in speciﬁc activity allows more radioactivity to be injected
into an animal. The number of detected events can be also
incremented by long scan time, whereas this approach is
limited by radionuclide half-life, radiotracers clearance, and
animal anesthesia duration [40]. In molecular imaging, PET
provides the possibility to visualize metabolic processes at
cellular level noninvasively, quantitatively, and repeatedly,
but does not allows a precise anatomic localization of
lesions. The introduction of micro-PET/CT hybrid systems
for imaging of small animals has greatly enhanced the
performance and the accuracy of nuclear imaging, allowing
a ﬁne spatial localization of the radiotracer biodistribution
and will facilitate the translation of molecular-based imaging
to humans. Delayed enhancement micro-CT, using blood-
pool and conventional iodinated contrast agent can help
to optimize measurement of infarct size, since molecu-
lar targets and biological processes diﬀer greatly between
necrotic and remote myocardium [29]. Micro-CT can be
also useful to perform attenuation correction that can result
in underestimation of regional radiotracer activity. Whereas
attenuationofthe511KeVphotonsisabout22%foramouse
[41], CT-based attenuation correction has been shown to
be accurate in small animal PET, allowing to reduce noise
and signiﬁcantly improve the accuracy of semiquantitative
uptake measurements [43]. Several scanner designs are
suited for diﬀerent preclinical research ﬁelds. Generally,
micro-CT provides higher spatial resolution (<500μm) than
current clinical scanner (from 450 to 600μm). Scaling down
CT imaging to the size of a mouse is challenging: to acquire
CT data with detail of internal organs comparable to clinical
CT scan, a resolution of about 100μmi sr e q u i r e d .T h e
heart rate of a mouse is about 400–600min−1 and to use
the diastole as the phase of the heart cycle that show the
minimum amount of motion, a CT temporal resolution
of almost 50ms is necessary in comparison to 300ms in
humans. In order to achieve high spatial and contrast
resolution, high X-ray doses are needed, ranging from 250 to
500mGy, in comparison to <50mGy for a clinical scanner.
Currently, ﬂat-panel-based mini-CT systems oﬀer a valuable
tradeoﬀ among resolution (200μm), scan time (0.5s), and
applied X-ray dose. Although these values remain below
the lethal level for the mouse (6Gy), repeated exposure to
small X-ray dosages can have biological eﬀects, which might
interfere with longitudinal imaging protocols, for example,
on tumor growth or hematopoiesis [44].
6. AnimalPreparationfor Cardiac
PET/CTImaging
Parallel to the development of dedicated PET scanners,
the need to optimize the operative protocols for small
rodents imaging has been proﬁled. For human F-18 FDG
studies, standard protocols have been established, whereas
procedures for animal imaging vary widely. In planning
longitudinal PET studies in mice, many variables interfering
with the accuracy of the experimental results must be taken
into account. Several factors may inﬂuence the kinetics and
biodistribution of radiopharmaceuticals, such as the mouse
preparation, the type of radiotracer employed, methods
and timing of radiopharmaceutical administration, and
anesthesia. Mice attending personnel should be trained for
resolutel and gentle manipulation. In fact, stress related to
physical restraint can induce corticosteroid and epinephrine
release, stimulate cardiovascular and respiratory functions,
andincreaseglucoselevels,bodytemperature,andanesthetic
dosages [45]. Moreover, restraint distress during F-18 FDG
injection can cause evident uptake of radiotracer in inter-
scapular brown fat and paraspinal muscles, interfering with
visualization of heart [45] .S e v e r a ls t u d i e sh a v ei n v e s t i g a t e d
the eﬀects of fasting, warming, and anesthesia on small
animal PET studies with FDG [46]. Under normal resting
conditions, myocardium derives the majority of energy from
long chain fatty acids, but it can rapidly change their energy
source to glucose in response to catecholamine or insulin
stimulation, or acute ischemia. It is reported that in fasted
mice myocardium should use fatty acids as its major energy
source, with consequently reduced glucose or FDG uptake
[47, 48]. In humans, glucose loading and insulin adminis-
tration are commonly used to improve image quality and
diagnostic accuracy. A glucose/insulin stimulation protocol
was successfully applied in rats [49] and in mice [50], to
standardizemetabolicconditionsforallanimalsandproduce
a 50-fold increase of FDG uptake into the myocardium. This
protocol provides intraperitoneal administration of 8mU/g
ofhumaninsulinand1mg/gofglucosethirtyminutesbefore
FDG injection, and a biodistribution of thirty minutes prior
to a static PET scan of heart. Keeping patients warm from
before the FDG injection to the end of PET scanning is a
standard practice, commonly adopted for reducing inter-
scapular brown fat uptake [45]. Fueger et al. [46]r e p o r t e d
that in mice warming signiﬁcantly reduces the intense FDG
uptake in brown adipose tissue, which could interfere with
a clear visualization of heart. In fact, at a so-called “zone8 Journal of Biomedicine and Biotechnology
of thermoneutrality” room temperature (30–34◦C), body
temperature is controlled by heat convection and activation
of brown adipose tissue and muscle activity are not required
to maintain it stable. Anesthesia can inﬂuence myocardial
metabolism and several haemodynamic parameters, such
as myocardial blood ﬂow. Lee et al. [51] compared the
eﬀects of ketamine-xylazine and pentobarbital anesthesia on
FDG biodistribution in fasted mice. They found that after 4
hours fast, both anesthetic protocols reduced FDG uptake in
myocardium.Thisﬁndingcanbeexplainedbythesigniﬁcant
increase in plasma glucose level brought by xylazine and
by the increased insulin level brought by pentobarbital.
Hildebrandt et al. [45] reported that isoﬂurane, compared
to ketamine-xylazine, induces mild hyperglycemia, reduces
FDG uptake by brown adipose tissue and increases it in
myocardium. Woo et al. [52] observed a dose-dependent
increase in FDG uptake in heart under isoﬂurane anesthesia,
likelyrelatedtoadose-dependentdecreaseinbloodpressure,
proportional to anesthetic depth.
Kober et al. [53] carried out regional myocardial blood
ﬂow under two commonly used anesthetic regimens in mice.
They reported that under ketamine 100mg/kg and xylazine
5mg/kg or isoﬂurane 1.25% the mean blood ﬂow value
in the LV myocardium was comparable. However, under
isoﬂurane concentration of about 2%, myocardial blood
ﬂow, and then the uptake of FDG or other radiotracers
increased remarkably. In fact, isoﬂurane has been shown to
have eﬀects on blood ﬂow and vascular resistance in many
tissues including the heart. Its dose-dependent vasodilatory
eﬀect on coronary microvessels has been assessed in vivo in
various animal models and in tissue preparations [53] and is
based on a mechanism of mitochondrial adenosine triphos-
phate regulated potassium (mitoKATP) channels opening
[54]. Ketamine/xylazine could enhance myocardial uptake of
radiotracers that interact with catecholamine receptors. Such
behavior seems to be due to a reduced blood norepinephrine
concentration and radiolabeled analogues activity, brought
about by the inhibition of norepinephrine release via α2-
adrenoreceptors agonist [55]. The volume of radiotracer
bolus should not exceed in mice 200μL for the risk of
iatrogenic hypervolemia and lung edema. Therefore, short
half-life radionuclides have a maximum time of use in
small rodents. Moreover their speciﬁc activity decreases over
time, increasing the number of molecules injected and the
potential appearance of side eﬀects. This problem is critical
in mice, because they receive a radiotracer dose greater of
humans: for example, in mouse is commonly used a dosage
of 0.2mCi of F-18 FDG, that is, 50 times greater than the
human one (10mCi), taking into account the body weight.
This factor is important to improve image quality but is
related to a higher radiation dose (about 40cGy for F-18
PET) [45]. The route of administration is another factor
that could inﬂuence kinetics and biodistribution of radio-
pharmaceuticals. In humans, radiotracers are commonly
administered intravenously and injection error occurs in
about 1% of patients [56]. The two most common ways
used in mice are intravenous and intraperitoneal injection.
In preclinical PET studies, intravenous injection is preferred,
because the circulation time is faster, the behavior of tracer
kinetic is analogue to human and no residual tracer remains
in peritoneum. The intraperitoneal route can be associated
with modiﬁcations in tracer kinetics, wide variability of
acquireddata,wrongradiotracerinjectionininternalorgans,
andinterferencewithabdominalstudies.However,duetothe
very small diameter of murine tail veins, partial paravenous
injection is common, leading to a net underestimation of the
injected dose. Therefore, like in humans [56], it has been
suggested the opportunity to measure residual radioactivity
in the tail with a short PET scan to correct the injected dose
forradioactivitydeposition[57].Moreover,Fuegeretal.[46]
foundthatat60minutesafterinjection,FDGbiodistribution
is comparable for intravenous and intraperitoneal route.
7.Postprocessingof PET/CTImages in
Models of MyocardialInfarction
The use of N-13 ammonia, rubidium-82, and F-18 FDG PET
for myocardial perfusion and viability imaging in patients
with CHD has increased signiﬁcantly over the last decade
[58–60]. PET allows noninvasive measurements of physio-
logical parameters in absolute units or semiquantitative data.
The quantitative assessment of regional tracer distribution
has represented the main improvement in clinical nuclear
cardiology. A reliable, automated, and reproducible analysis
of cardiac SPECT or PET data is an important goal and
several software programs perform quantitative analysis of
myocardial perfusion and viability, according to a scheme
divided into some basic steps. First, the myocardial emission
activity from the left ventricle is “segmented,” that is isolated
fromanyotheradjacentemissionactivity.Sincetomographic
PET images are usually acquired transaxially to the long
axis of the patient, the cardiac images must be reoriented
by deﬁning its long axis. Some software programs also
allow deﬁning the valve plane and the junction between
left and right ventricle. At this point, the tomographic PET
data of the heart can be reprocessed into short axis slices
(from apex to the base, perpendicularly to the long axis of
the heart), vertical long axis slices (from the posterior to
anterior wall, parallel to long axis of the heart), horizontal
long axis (from the lateral wall to septum, parallel to the
long axis of the heart) to help the user in validating the
reorientation. Assuming a simpliﬁed structural model of
the left ventricle, described as a cylindrical structure in its
basal two-thirds and spherical at the base, a regular sampling
of maximal activity (in 30–60 equally spaced points) is
conducted from each short axis section, and along rays
normal to the myocardium. These data are used to compute
a two-dimensional representation of midmyocardium called
“circumferential proﬁle.” The epicardial and endocardial
surfaces are located at ﬁxed standard deviation values below
the midmyocardial maxima. Circumferential proﬁles are
arranged as a series of concentric circles, proportionally
to the number of short axis slices, in a “polar map.” A
polar map is a two-dimensional representation of the three-
dimensional distribution of the radiotracer in the heart, with
the apex corresponding to the center, and the outermostJournal of Biomedicine and Biotechnology 9
Figure 4: [18F] FDG PET. Left ventricular polar map obtained in a normal mouse (top) and in a mouse with myocardial infarction (lower)
by MunichHeart software.
circle corresponding to the base of the left ventricle [61–
63]. Epicardial and endocardial surfaces can be used for
displaying 3D rendering of myocardial perfusion that can be
rotated and viewed as a color mapping of perfusion or as
a wire-mesh frame. The regional distribution of radiotracer
activity in LV myocardium (lateral, anterior, septal, inferior,
and apical quadrant of the polar display) can be expressed
in MBq/mL, standard uptake value, and standard deviation
from maximal myocardial activity. However, a normal
threshold for quantify infarct size has not yet been reported.
Severalalgorithmsforquantiﬁcationofmyocardialperfusion
are based on the development and validation of a normal
database or by measures obtained from anthropomorphic
phantoms; others display all perfusion values below 50%
as blackout pixels [61, 63, 64]. Generally polar maps are
normalized for maximum activity value and scaled from
0 to maximum activity of 100%. Consequently, defects in
perfusion are commonly expressed in percentage value by
counting the number of pixels in the polar map whose
the activity is below normal threshold and relate this value
to the total number of pixels. Moreover, it is possible to
determine the standard deviation from the normal threshold
value for the pixels whose count is considered below normal
[62] or measure infarct size in cm2 using the calculated
individual element size [61, 63]. Blackout pixels in the polar
map are used as visual indication of perfusion defect size.
Although the quantiﬁcation of infarct size has been well
established in humans with PET, this approach is more
challenging in small animals due to their smaller size.
In preclinical cardiovascular research, FDG PET is useful
to accurately evaluate myocardial glucose metabolism and
infarct size, monitoring in vivo and noninvasively the same
animal. Its accurate and serial quantiﬁcation may allow
future applications in diﬀerent knockout and to evaluate
postischemic treatments, such as new drugs, gene therapy,
or stem cells. The assessment of myocardial perfusion
and viability by PET has been described in rodents, with
the help of automated software owners [32, 65], clinical
software’s (Scion Image, ImageJ) [64, 66], or dedicated
programs [31, 33, 49]. The validation of quantitative PET
analysis methods developed for small laboratory rodents has
been performed by histomorphometry [31, 49, 66]o rb y
autoradiography as the gold standard [32, 64]. The threshold
value of normal myocardial perfusion to accurately measure
the extent of the necrotic area was determined by linear
regression for comparison with histological measurements
[46], or based on the method described by O’Connor et al.
[67], providing that the pixel values less than 50% of
maximum activity correspond to myocardial hypoperfused
areas. Necrotic pattern was deﬁned as relative tracer uptake
of <50% of maximal myocardial uptake. PET can also
be used to measure changes in anatomic and functional
parameters, such as LV shape, end-diastolic and end systolic,
volumes, stroke volumes, cardiac output, ejection fraction,
and regional contractility [32], occurring in postinfarction
cardiac remodeling (Figure 4).10 Journal of Biomedicine and Biotechnology
8. Conclusions
In the last decades, murine models of MI have become
useful tools to highlight the mechanisms underlying CHD
and to test new therapeutic approaches, such as gene or stem
cells therapy. At the same time, with technological advance-
ments, small laboratory PET/CT imaging has emerged in
cardiovascular research, providing in vivo a noninvasive,
serial and quantitative assessment of myocardial perfusion
and metabolism at a molecular level. PET/CT studies of
myocardial perfusion and viability have been successful
tools to perform a quantitative evaluation of myocardial
metabolism and to measure infarct size in an accurate and
repeatable way both in clinical and in preclinical research.
Since the same animal can be imaged repeatedly and each
animal can be its own control, the number of animals
examined is signiﬁcantly reduced and the variability caused
by interindividual diﬀerences is removed, according to the
principle of “reﬁnement, reduction, and replacement.”
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